Article Details

Voyager's Single-Dose AAV Strategy for Silencing Tau for Alzheimer Disease - CGTLive®

Retrieved on: 2025-08-12 22:26:32

Tags for this article:

Click the tags to see associated articles and topics

Voyager's Single-Dose AAV Strategy for Silencing Tau for Alzheimer Disease - CGTLive®. View article details on hiswai:

Excerpt

Rajeev Sivasankaran, PhD, vice president of neuroscience at Voyager Therapeutics, discussed preclinical data on the company's AAV-delivered RNA ...

Article found on: www.cgtlive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo